GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Beneish M-Score

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Beneish M-Score : 0.00 (As of May. 05, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Progenics Pharmaceuticals's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Progenics Pharmaceuticals was 0.00. The lowest was 0.00. And the median was 0.00.


Progenics Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Progenics Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Beneish M-Score Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 302.33 1.51 -0.22 -2.68 0.29

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.36 -1.32 -2.22 0.29 -1.52

Competitive Comparison of Progenics Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Progenics Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progenics Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Beneish M-Score falls into.



Progenics Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Progenics Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5673+0.528 * 1.1466+0.404 * 1.832+0.892 * 2.2109+0.115 * 1.0008
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6952+4.679 * -0.032468-0.327 * 1.3935
=-1.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar20) TTM:Last Year (Mar19) TTM:
Total Receivables was $6.19 Mil.
Revenue was 6.248 + 15.126 + 5.613 + 9.966 = $36.95 Mil.
Gross Profit was 4.69 + 13.768 + 4.296 + 9.473 = $32.23 Mil.
Total Current Assets was $40.55 Mil.
Total Assets was $98.34 Mil.
Property, Plant and Equipment(Net PPE) was $27.95 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.55 Mil.
Selling, General, & Admin. Expense(SGA) was $49.12 Mil.
Total Current Liabilities was $19.10 Mil.
Long-Term Debt & Capital Lease Obligation was $45.00 Mil.
Net Income was -16.801 + -11.275 + -18.842 + -19.7 = $-66.62 Mil.
Non Operating Income was 0.239 + 0.673 + 0.434 + -0.985 = $0.36 Mil.
Cash Flow from Operations was -7.607 + -18.827 + -17.171 + -20.181 = $-63.79 Mil.
Total Receivables was $4.94 Mil.
Revenue was 4.281 + 3.238 + 5.317 + 3.878 = $16.71 Mil.
Gross Profit was 4.281 + 3.238 + 5.317 + 3.878 = $16.71 Mil.
Total Current Assets was $117.65 Mil.
Total Assets was $164.20 Mil.
Property, Plant and Equipment(Net PPE) was $19.36 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.77 Mil.
Selling, General, & Admin. Expense(SGA) was $31.96 Mil.
Total Current Liabilities was $24.45 Mil.
Long-Term Debt & Capital Lease Obligation was $52.36 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6.19 / 36.953) / (4.935 / 16.714)
=0.16751 / 0.295261
=0.5673

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(16.714 / 16.714) / (32.227 / 36.953)
=1 / 0.872108
=1.1466

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (40.546 + 27.952) / 98.344) / (1 - (117.647 + 19.355) / 164.204)
=0.303486 / 0.16566
=1.832

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=36.953 / 16.714
=2.2109

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.768 / (1.768 + 19.355)) / (2.551 / (2.551 + 27.952))
=0.0837 / 0.083631
=1.0008

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(49.123 / 36.953) / (31.958 / 16.714)
=1.329337 / 1.91205
=0.6952

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((44.998 + 19.099) / 98.344) / ((52.355 + 24.446) / 164.204)
=0.651763 / 0.467717
=1.3935

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-66.618 - 0.361 - -63.786) / 98.344
=-0.032468

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Progenics Pharmaceuticals has a M-score of -1.61 signals that the company is likely to be a manipulator.


Progenics Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.
Executives
Asha Das officer: Chief Medical Officer C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli director SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman 10 percent owner, other: See Explanation of Responses FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria 10 percent owner, other: See Explanation of Responses 1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams director
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Headlines

From GuruFocus

Progenics Sends Letter to Shareholders

By Marketwired Marketwired 10-10-2019